Form 4: Vyne Therapeutics Inc. Executive Iain Stuart Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Chief Scientific Officer Iain Stuart reports a transaction involving Vyne Therapeutics Inc. common stock due to tax withholding requirements.
Summary
- On April 1, 2024, Iain Stuart, Chief Scientific Officer of Vyne Therapeutics Inc., had 157 shares of common stock disposed of to satisfy tax withholding requirements related to the vesting of restricted stock units.
- The price per share was $3.08.
- Following the transaction, Stuart directly owns 133,741 shares of Vyne Therapeutics Inc. common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock transactions for tax purposes, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard procedure for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of transaction involving the disposal of common stock. |
| 04/03/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.